52 related articles for article (PubMed ID: 15505621)
1. Immunological evaluation of personalized peptide vaccination in combination with UFT and UZEL for metastatic colorectal carcinoma patients.
Hattori T; Mine T; Komatsu N; Yamada A; Itoh K; Shiozaki H; Okuno K
Cancer Immunol Immunother; 2009 Nov; 58(11):1843-52. PubMed ID: 19396597
[TBL] [Abstract][Full Text] [Related]
2. Cold-associated laryngopharyngeal dysesthesia syndrome after oxaliplatin treatment.
Babacan A
J Oncol Pharm Pract; 2024 May; ():10781552241255289. PubMed ID: 38778702
[TBL] [Abstract][Full Text] [Related]
3. Effects of bolus injection of 5-fluorouracil on steady-state plasma concentrations of 5-fluorouracil in Japanese patients with advanced colorectal cancer.
Tamura T; Kuwahara A; Kadoyama K; Yamamori M; Nishiguchi K; Inokuma T; Takemoto Y; Chayahara N; Okuno T; Miki I; Fujishima Y; Sakaeda T
Int J Med Sci; 2011; 8(5):406-12. PubMed ID: 21750645
[TBL] [Abstract][Full Text] [Related]
4. Role of oxaliplatin in the treatment of colorectal cancer.
Comella P; Casaretti R; Sandomenico C; Avallone A; Franco L
Ther Clin Risk Manag; 2009 Feb; 5(1):229-38. PubMed ID: 19436599
[TBL] [Abstract][Full Text] [Related]
5. Alternating irinotecan with oxaliplatin combined with UFT plus leucovorin (SCOUT) in metastatic colorectal cancer.
Sheikh HY; Valle JW; Waddell T; Palmer K; Wilson G; Sjursen A; Craven O; Swindell R; Saunders MP
Br J Cancer; 2008 Aug; 99(4):577-83. PubMed ID: 18682717
[TBL] [Abstract][Full Text] [Related]
6. Metastatic colorectal cancer: current systemic treatment options.
Board RE; Valle JW
Drugs; 2007; 67(13):1851-67. PubMed ID: 17722954
[TBL] [Abstract][Full Text] [Related]
7. Uracil/ftorafur/leucovorin combined with irinotecan (TEGAFIRI) or oxaliplatin (TEGAFOX) as first-line treatment for metastatic colorectal cancer patients: results of randomised phase II study.
Bajetta E; Di Bartolomeo M; Buzzoni R; Mariani L; Zilembo N; Ferrario E; Lo Vullo S; Aitini E; Isa L; Barone C; Jacobelli S; Recaldin E; Pinotti G; Iop A
Br J Cancer; 2007 Feb; 96(3):439-44. PubMed ID: 17245343
[TBL] [Abstract][Full Text] [Related]
8. Oncopaz cooperative group.
González Barón M; Espinosa E
Clin Transl Oncol; 2006 Mar; 8(3):145-7. PubMed ID: 16648112
[No Abstract] [Full Text] [Related]
9. Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma.
Pazdur R; Lassere Y; Rhodes V; Ajani JA; Sugarman SM; Patt YZ; Jones DV; Markowitz AB; Abbruzzese JL; Bready B
J Clin Oncol; 1994 Nov; 12(11):2296-300. PubMed ID: 7964943
[TBL] [Abstract][Full Text] [Related]
10. Oral Tegafur-Uracil Combination plus Leucovorin versus Other Fluoropyrimidine Agents in Colorectal Cancer: A Systematic Review and Meta-Analysis.
Kataria SP; Nagar M; Verma S; Purohit V
South Asian J Cancer; 2022 Jan; 11(1):84-94. PubMed ID: 35833043
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of UFT and oxaliplatin in first-line treatment of advanced colorectal cancer.
Feliu J; Vicent JM; García-Girón C; Constela M; Fonseca E; Aparicio J; Lomas M; Antón-Aparicio L; Dorta FJ; Gonzalez-Baron M;
Br J Cancer; 2004 Nov; 91(10):1758-62. PubMed ID: 15505621
[TBL] [Abstract][Full Text] [Related]
12. Concurrent irinotecan, oxaliplatin and UFT in first-line treatment of metastatic colorectal cancer: a phase I study.
Sheikh HY; Valle JW; Palmer K; Sjursen A; Craven O; Wilson G; Swindell R; Saunders MP
Br J Cancer; 2007 Jan; 96(1):38-43. PubMed ID: 17213824
[TBL] [Abstract][Full Text] [Related]
13. 'A phase II study of oral uracil/ftorafur (UFT) plus leucovorin combined with oxaliplatin (TEGAFOX) as first-line treatment in patients with metastatic colorectal cancer'.
Bennouna J; Perrier H; Paillot B; Priou F; Jacob JH; Hebbar M; Bordenave S; Seitz JF; Cvitkovic F; Dorval E; Malek K; Tonelli D; Douillard JY
Br J Cancer; 2006 Jan; 94(1):69-73. PubMed ID: 16404362
[TBL] [Abstract][Full Text] [Related]
14. UFT/leucovorin and oxaliplatin alternated with UFT/leucovorin and irinotecan in metastatic colorectal cancer.
Petrioli R; Sabatino M; Fiaschi AI; Marsili S; Pozzessere D; Messinese S; Correale P; Civitelli S; Tanzini G; Tani F; De Martino A; Marzocca G; Lorenzi M; Giorgi G; Francini G
Br J Cancer; 2004 Jan; 90(2):306-9. PubMed ID: 14735168
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
